Study of ALK-001 on the Progression of Stargardt Disease

Summary

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

Timeline

Start

2026-06

Primary completion

2029-10

Completion

2030-12

Drugs

Indications